Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters

Show simple item record

dc.contributor.author Vuorio, Alpo
dc.contributor.author Kovanen, Petri T.
dc.date.accessioned 2019-01-24T10:19:01Z
dc.date.available 2019-01-24T10:19:01Z
dc.date.issued 2018-12
dc.identifier.citation Vuorio , A & Kovanen , P T 2018 , ' Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters ' , Nutrients , vol. 10 , no. 12 , 1842 . https://doi.org/10.3390/nu10121842
dc.identifier.other PURE: 121572649
dc.identifier.other PURE UUID: 31d7d2ba-c89f-4b3b-83bd-f8eff3d1acf5
dc.identifier.other WOS: 000455073200023
dc.identifier.other Scopus: 85057764270
dc.identifier.uri http://hdl.handle.net/10138/298295
dc.description.abstract This review covers the current knowledge about plant stanol esters as a dietary treatment option for heterozygous familial hypercholesterolemia (he-FH) children. The current estimation of the prevalence of he-FH is about one out of 200-250 persons. In this autosomal dominant disease, the concentration of plasma low-density lipoprotein cholesterol (LDL-C) is strongly elevated since birth. Quantitative coronary angiography among he-FH patients has revealed that stenosing atherosclerotic plaques start to develop in he-FH males in their twenties and in he-FH females in their thirties, and that the magnitude of the plaque burden predicts future coronary events. The cumulative exposure of coronary arteries to the lifelong LDL-C elevation can be estimated by calculating the LDL-C burden (LDL-C level x years), and it can also be used to demonstrate the usefulness of dietary stanol ester treatment. Thus, when compared with untreated he-FH patients, the LDL-C burden of using statin from the age of 10 is 15% less, and if he-FH patients starts to use dietary stanol from six years onwards and a combination of statin and dietary stanol from 10 years onwards, the LDL-C burden is 21% less compared to non-treated he-FH patients. We consider dietary stanol treatment of he-FH children as a part of the LDL-C-lowering treatment package as safe and cost-effective, and particularly applicable for the family-centered care of the entire he-FH families. en
dc.format.extent 10
dc.language.iso eng
dc.relation.ispartof Nutrients
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject phytosterol
dc.subject stanol
dc.subject diet
dc.subject familial hypercholesterolemia
dc.subject coronary heart disease
dc.subject hypercholesterolemia
dc.subject children
dc.subject family
dc.subject atherosclerosis
dc.subject low-density cholesterol
dc.subject PHYTOSTEROLS/-STANOLS
dc.subject GENERAL-POPULATION
dc.subject SERUM-CHOLESTEROL
dc.subject FUNCTIONAL FOODS
dc.subject POSITION PAPER
dc.subject HEART-DISEASE
dc.subject NORTH KARELIA
dc.subject STEROL
dc.subject MANAGEMENT
dc.subject DIAGNOSIS
dc.subject 3143 Nutrition
dc.title Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters en
dc.type Review Article
dc.contributor.organization Department of Forensic Medicine
dc.contributor.organization Medicum
dc.contributor.organization University of Helsinki
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3390/nu10121842
dc.relation.issn 2072-6643
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
nutrients_10_01842.pdf 887.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record